Accent Therapeutics has initiated dosing for the first patient in its Phase 1/2 trial of ATX-559, alongside a change in its Chief Scientific Officer.

Anaptys reveals that the Phase 2b trial for ANB032, a BTLA agonist, failed to achieve its main and secondary objectives in treating atopic dermatitis.

Leriglitazone achieved its main goal in the NEXUS trial, which is crucial for children with cerebral Adrenoleukodystrophy.

Zealand Pharma reports enrollment of the first participant in the Phase 2b ZUPREME-1 study of petrelintide for individuals with overweight or obesity.

ALX Oncology reveals new findings showing that the combination of Evorpacept and Zanidatamab shows encouraging anticancer effects in advanced breast cancer.

Arvinas and Pfizer Share Early Phase 1b Results from TACTIVE-U Sub-Study on Vepdegestrant Plus Abemaciclib at the 2024 San Antonio Breast Cancer Symposium.

Halia Therapeutics reports encouraging preliminary results and moves to the next phase of its Phase 2 trial for HT-6184 in patients with low-risk myelodysplastic syndromes (LR-MDS).

Moberg Pharma announces key results from its phase 3 trial in North America and will reclaim the EU rights to MOB-015.

Astria Therapeutics has received FDA approval for its IND application concerning STAR-0310, a monoclonal antibody targeting OX40, aimed at treating atopic dermatitis.

Apogee Therapeutics has dosed the initial participants in a Phase 1 clinical trial for APG333.

NextCure, announced FDA approval of its IND application to begin a Phase 1 trial for LNCB74.

Protara reports favorable outcomes from the current Phase 2 ADVANCED-2 study of TARA-002 in NMIBC patients.